UC Berkeley

Background

Several per- and polyfluoroalkyl substances (PFAS) are ubiquitous anthropogenic pollutants almost universally detected in humans. Experimental evidence indicates that PFAS alter glucose metabolism and insulin secretion. However, epidemiological studies have yielded inconsistent results.

Objective

We sought to examine associations between plasma PFAS concentrations, glycemic indicators, and diabetes incidence among high-risk adults.

Methods

Within the Diabetes Prevention Program (DPP), a trial for the prevention of type 2 diabetes among high-risk individuals, we quantified baseline plasma concentrations of nine PFAS among 957 participants randomized to a lifestyle intervention or placebo. We evaluated adjusted associations for plasma PFAS concentrations with diabetes incidence and key glycemic indicators measured at baseline and annually over up to 4.6 y.

Results

Plasma PFAS concentrations were similar to those reported in the U.S. population in 1999-2000. At baseline, in cross-sectional analysis, a doubling in plasma perfluorooctanesulfonic acid (PFOS) and perfluorooctanoic acid (PFOA) concentrations was associated with higher homeostatic model assessment of insulin resistance (HOMA-IR) [β_PFOS=0.39; 95% confidence interval (CI): 0.13, 0.66; β_PFOA=0.64; 95% CI: 0.34, 0.94], β-cell function (HOMA-β) (β_PFOS=9.62; 95% CI: 1.55, 17.70; β_PFOA=15.93; 95% CI: 6.78, 25.08), fasting proinsulin (β_PFOS=1.37 pM; 95% CI: 0.50, 2.25; β_PFOA=1.71 pM; 95% CI: 0.72, 2.71), and glycated hemoglobin (HbA_1c) (β_PFOS=0.03%; 95% CI: 0.002, 0.07; β_PFOA=0.04%; 95% CI: 0.001, 0.07). There was no strong evidence of associations between plasma PFAS concentrations and diabetes incidence or prospective changes in glycemic indicators during the follow-up period.

Conclusions

At baseline, several PFAS were cross-sectionally associated with small differences in markers of insulin secretion and β-cell function. However, there was limited evidence suggesting that PFAS concentrations are associated with diabetes incidence or changes in glycemic indicators during the follow-up period. https://doi.org/10.1289/EHP1612.